Trial Profile
A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2023
Price :
$35
*
At a glance
- Drugs Bexarotene (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 13 Dec 2022 Status changed from active, no longer recruiting to completed.
- 20 Jul 2021 Planned primary completion date changed from 28 Nov 2022 to 1 Aug 2021.
- 20 Jul 2021 Status changed from recruiting to active, no longer recruiting.